Drug testing and analysis
January 1, 2014
Hamilton Morris, Jason Wallach
240 citations
More than 30 dissociative compounds have been used non-medically over the past 60 years, starting with PCP in the 1950s and later including ketamine and dextromethorphan. At least 14 PCP derivatives were sold illicitly from the 1960s to the 1990s. The Internet transformed the drug market, shifting from gray-market vendors to online research chemical suppliers. The first dissociative research chemical, 4-MeO-PCP, appeared in 2008, and the market now includes at least 12 dissociatives, nearly half previously unknown in scientific literature. Methoxetamine achieved widespread international use. This historical account presents the first complete portrait of the underground dissociative market, alongside legal, technological, and scientific developments driving its evolution.
Drug testing and analysis
February 1, 2018
Tristan Colestock, Jason Wallach, Matt Mansi et al.
14 citations
A new dissociative anesthetic, 3-MeO-PCMo, a morpholine analogue of 3-MeO-PCP, was synthesized and characterized along with five related compounds. All six arylcyclohexylmorpholines were analyzed using chromatographic, mass spectrometric, and spectroscopic techniques, allowing differentiation of positional isomers. In vitro binding studies in rat forebrain preparations showed moderate affinity for the N-methyl-D-aspartate receptor (NMDAR), with 3-Me-PCMo having the highest affinity, followed by 3-MeO-PCMo. 3-MeO-PCMo had affinity comparable to ketamine and approximately 12-fold lower than PCP. These findings support anecdotal reports of dissociative effects from 3-MeO-PCMo in humans.
Journal of Behavioral and Brain Science
January 1, 2023
Melissa C. Selinger, David M. Compton, Hamilton Morris et al.
3 citations
Managing patients with both chronic pain and major depressive disorder is challenging, and many do not benefit adequately from standard medications. A retrospective review of cases explored patient satisfaction and tolerability of a novel virtual reality protocol used alongside intravenous ketamine infusions. Pain scores on a visual analogue scale were significantly lower on the third treatment day than on the first. Depression ratings also improved after infusions and across sessions. Two-thirds of patients preferred having virtual reality with their ketamine infusion. The findings suggest potential for combination therapy, but prospective studies are needed to confirm any synergistic benefit.